EGFR-TKI SENSITIZING MUTATION
Clinical trials for EGFR-TKI SENSITIZING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR-TKI SENSITIZING MUTATION trials appear
Sign up with your email to follow new studies for EGFR-TKI SENSITIZING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lung cancer drug dose doubled for stubborn tumors in new trial
Disease control Not yet recruitingThis study tests whether a higher dose (160 mg) of the targeted drug firmonertinib can shrink or control advanced EGFR-mutant lung cancer in people whose tumors stayed stable after 8 weeks on the standard 80 mg dose. About 28 adults with stage IV non-small cell lung cancer and no…
Matched conditions: EGFR-TKI SENSITIZING MUTATION
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 17, 2026 10:41 UTC
-
New hope for lung cancer patients with brain spread: targeted drug plus brain chemo
Disease control Not yet recruitingThis study tests a combination of a targeted drug (zorifertinib) and chemotherapy given directly into the fluid around the brain for people with a type of lung cancer that has spread to the lining of the brain. The goal is to control the disease and improve survival. About 38 adu…
Matched conditions: EGFR-TKI SENSITIZING MUTATION
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 13, 2026 16:03 UTC